Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
Department of Pathology, Hartford Hospital, Hartford, Connecticut, USA.
J Clin Microbiol. 2017 Dec;55(12):3502-3512. doi: 10.1128/JCM.01241-17. Epub 2017 Oct 11.
The effectiveness of antimicrobial binding resins present in blood culture (BC) bottles in removing meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam is unknown. We assessed the time to detection (TTD) and growth of 2 isolates in the presence of clinically meaningful concentrations of these antibiotics. Bactec Plus Aerobic/F and BacT/Alert FA Plus BC bottles were inoculated with one of two isolates (1 meropenem susceptible and 1 resistant), followed by fresh whole blood containing the peak, midpoint, or trough plasma concentrations for meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam. Matching bottles were loaded into their respective detection instruments and a standard incubator at 37°C, with TTD and CFU being monitored for up to 72 h. Bacterial growth was observed for 11/48 (22.9%), 22/48 (45.8%), and 47/48 (97.9%) of all BC bottles inoculated with the peak, midpoint, and trough concentrations, respectively ( ≤ 0.001). When was isolated, the TTD was typically <26 h, and no differences between Bactec and BacT/Alert bottles were observed. In both systems, meropenem was removed to a greater degree than were ceftolozane and ceftazidime; however, concentrations for all antibiotics remained above the MIC for the susceptible organisms at 12 h. BC bottles containing antibiotic binding resins may not sufficiently inactivate achievable concentrations of meropenem, ceftolozane-tazobactam, and ceftazidime-avibactam. The consistent identification of both isolates was observed only in the presence of antibiotic trough concentrations. To minimize false-negative BC results for patients already receiving these antibiotics, cultures should be collected just prior to the next dose, when antibiotic concentrations are lowest.
血液培养瓶中抗菌结合树脂对美罗培南、头孢他洛酯-他唑巴坦和头孢他啶-阿维巴坦的去除效果尚不清楚。我们评估了这些抗生素在临床相关浓度下两种分离株的检出时间(TTD)和生长情况。在一个含有两种分离株(1 株美罗培南敏感株和 1 株耐药株)的 Bactec Plus Aerobic/F 和 BacT/Alert FA Plus BC 瓶中接种,随后用含有美罗培南、头孢他洛酯-他唑巴坦和头孢他啶-阿维巴坦的峰值、中点或谷值血浆浓度的新鲜全血进行接种。将匹配的瓶子装入各自的检测仪器和 37°C 的标准孵育箱中,监测 TTD 和 CFU 长达 72 小时。分别用峰值、中点和谷值浓度接种的 48 个 BC 瓶中,有 11/48(22.9%)、22/48(45.8%)和 47/48(97.9%)观察到细菌生长(≤0.001)。当分离出 时,TTD 通常<26 小时,Bactec 和 BacT/Alert 瓶之间没有观察到差异。在这两种系统中,美罗培南的去除程度大于头孢他洛酯和头孢他啶;然而,所有抗生素的浓度在 12 小时时仍高于敏感菌的 MIC。含有抗生素结合树脂的 BC 瓶可能无法充分灭活可达到的美罗培南、头孢他洛酯-他唑巴坦和头孢他啶-阿维巴坦浓度。仅在存在抗生素谷值浓度时才观察到两种分离株的一致鉴定。为了最大限度地减少对已接受这些抗生素治疗的患者的 BC 结果出现假阴性,应在下一次剂量前采集培养物,此时抗生素浓度最低。